Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice
Tirzepatide and semaglutide exhibited similar potent glucose-lowering effects. At concentrations used in the present experiments, tirzepatide exhibited more beneficial effects on β-cell-related gene expression, insulin granule count and glucose-stimulated insulin secretion compared to semaglutide. In addition, tirzepatide exhibited a stronger favourable effect on hepatic fat deposition and improved inflammation in the liver. This is the first report showing that tirzepatide, a novel diabetes drug, exhibits a superior effect on pancreatic β-cells and the liver of obese type 2 diabetic mice.
Authors
- Tomoatsu Mune
- Hideaki Kaneto (ORCID: https://orcid.org/0000-0001-7898-1943)
- Kohei Kaku (ORCID: https://orcid.org/0000-0003-1574-0565)
- Yuka Nogami
- Junpei Sanada (ORCID: https://orcid.org/0000-0002-9794-9444)
- Shuhei Nakanishi (ORCID: https://orcid.org/0000-0003-2640-9632)
- Yoshiko Shirakiya
- Yuichiro Iwamoto (ORCID: https://orcid.org/0000-0001-8162-359X)
- Yukino Katakura
- Tomohiko Kimura (ORCID: https://orcid.org/0000-0003-3986-9494)
- Masashi Shimoda (ORCID: https://orcid.org/0000-0002-4223-9613)
- Kazunori Dan
- Yuki Yamasaki (ORCID: https://orcid.org/0000-0003-0007-9583)
- Yoshiro Fushimi (ORCID: https://orcid.org/0000-0002-9618-8698)
- Hideyuki Iwamoto (ORCID: https://orcid.org/0009-0004-5654-2578)
Institutions
- Kawasaki Medical School (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1111/dom.15972
- Citations
- 12
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.29